PSI Sci
New here? Follow the money and the votes · Not sure of your district? Find your U.S. House member · Find your state legislators

H.R. 3537: Accelerating Access to Critical Therapies for ALS Act

Before you vote › Federal bills

H.R. 3537: Accelerating Access to Critical Therapies for ALS Act

117th Congress · introduced 2021-05-25 · Health · Latest: Became Public Law No: 117-79.

AI-relatedfederal

Follow this bill, step by step

  1. Where it came from: introduced 2021-05-25 · official record
  2. Who proposed it: Rep. Quigley, Mike [D-IL-5] · what a sponsor is
  3. What happened next: 1 recorded vote in our records. Latest: House roll call 415 (2021): On Motion to Suspend the Rules and Pass, as Amended, HR3537 (2021-12-08), Passed. See all
  4. Where it stands now: Became Public Law No: 117-79. (final step reached)
  5. If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.

What does this mean?

Official title

Accelerating Access to Critical Therapies for ALS Act

Plain summary

Accelerating Access to Critical Therapies for ALS Act This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions. The Department of Health and Human Services (HHS) shall award grants to eligible entities for scientific research utilizing data from expanded access to investigational ALS treatments for individuals who are not otherwise eligible for clinical trials. The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other rare neurodegenerative diseases. HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases. The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases. The Government Accountability Office must report to Congress about the grants provided under this bill, including an analysis of the impact of such grants on research and development of treatments for ALS.

Congressional Research Service summary (Public Law), quoted unchanged (nonpartisan). Read the source.

What a vote does

A “Yea” vote

If it passes both chambers and is signed, it becomes law.

A “Nay” vote

If it is not passed, current law stays as it is.

PSI Sci description of the legislative step (not an opinion).

What does this mean? (plain words)

Official text

Accelerating Access to Critical Therapies for ALS Act

Source: Congressional Research Service summary (Public Law)

AI explanation – may be wrong, check the official text

No AI explanation yet. It takes up to a minute to write and is then saved for everyone.

Limited to a few requests an hour per person.

The strongest published arguments

Arguments for (supporters)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Arguments against (opponents)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Rep. Quigley, Mike [D-IL-5] · 331 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

Brendan F. Boyle (D-PA), Seth Moulton (D-MA), Salud O. Carbajal (D-CA), John B. Larson (D-CT), Madeleine Dean (D-PA), Thomas R. Suozzi (D-NY), Nydia M. Velázquez (D-NY), Mike Levin (D-CA), Eleanor Holmes Norton (D-DC), William R. Timmons IV (R-SC), Jefferson Van Drew (R-NJ), Ken Calvert (R-CA), William R. Keating (D-MA), Mario Diaz-Balart (R-FL), Earl L. "Buddy" Carter (R-GA), Lucy McBath (D-GA), Jason Smith (R-MO), Michael R. Turner (R-OH), Adrian Smith (R-NE), Glenn Grothman (R-WI), John H. Rutherford (R-FL), David Schweikert (R-AZ), Jason Crow (D-CO), Brett Guthrie (R-KY), Brian K. Fitzpatrick (R-PA), Betty McCollum (D-MN), Austin Scott (R-GA), James R. Baird (R-IN), David G. Valadao (R-CA), John R. Moolenaar (R-MI), Stephen F. Lynch (D-MA), Jimmy Panetta (D-CA), Andy Kim (D-NJ), Gwen Moore (D-WI), Janice D. Schakowsky (D-IL), Mike Thompson (D-CA), Ruben Gallego (D-AZ) and 271 more.

Sponsor's campaign money: Rep. Quigley, Mike [D-IL-5] reported raising $998,074 (2025–2026). Details. Shown for context only; it does not mean any donor supported this bill.

Recorded votes

Words on this page, explained (1)
Bill
A proposed law. It becomes law only if it passes the legislature and is signed by the president or governor (or a veto is overridden).

Plain meanings written from linked sources. All words.

Sources

Record fed-us-cong117-hr3537 · catalog fed-us-congress-bills-cong117 · updated 2026-11-15 by psicol fed-bills-cong117